|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of gastric cancer显示文摘The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance | Michele Orditura Gennaro Galizia Vincenzo Sforza Valentina Gambardella Alessio Fabozzi Maria Maddalena Laterza Francesca Andreozzi Jole Ventriglia Beatrice Savastano Andrea Mabilia Eva Lieto Fortunato Ciardiello Ferdinando De Vita | 2014 | World Journal of Gastroenterology2014，20，7： | 116 |
| 2 | Clinical management of advanced gastric cancer: The role of new molecular drugs显示文摘Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States.Surgery represents the main approach for this disease but,notwithstanding the advances in surgical techniques,we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates.Despite the development of new drugs has significantly improved the effectiveness of chemothera-py,the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor.Recently,several molecular target agents have been investigated;in particular,trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients.New molecules targeting vascular epithelial growth factor,mammalian target of rapamycin,and anti hepatocyte growth factor-c-Met pathway are also under investigation,with interesting results.Anyway,it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results.In this paper we review the actual'scenario'of targeted treatments,also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma,discussing their efficacy and potential applications in clinical practice. | Ferdinando De Vita Natale Di Martino Alessio Fabozzi Maria Maddalena Laterza Jole Ventriglia Beatrice Savastano Angelica Petrillo Valentina Gambardella Vincenzo Sforza Luigi Marano Annamaria Auricchio Gennaro Galizia Fortunato Ciardiello Michele Orditura | 2014 | World Journal of Gastroenterology2014，20，40： | 12 |
| 3 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets显示文摘In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer(m CRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the RAS-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with m CRC. In this review, we describe approved targeted therapies for the management of metastatic m CRC and discuss new candidate targets on the horizon. | Giulia Martini Teresa Troiani Claudia Cardone Pietropaolo Vitiello Vincenzo Sforza Davide Ciardiello Stefania Napolitano Carminia Maria Della Corte Floriana Morgillo Antonio Raucci Antonio Cuomo Francesco Selvaggi Fortunato Ciardiello Erika Martinelli | 2017 | World Journal of Gastroenterology2017，23，26： | 7 |
| 4 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer显示文摘The prognosis of patients with metastatic colorectal cancer(m CRC) remain poor despite the impressive improvement of treatments observed over the last 20 years that led to an increase in median overall survival from 6 mo, with the only best supportive care, to approximately 30 mo with the introduction of active chemotherapy drugs and targeted agents. The monoclonal antibodies(mo Abs) cetuximab and panitumumab, directed against the epidermal growth factor receptor(EGFR), undoubtedly represent a major step forward in the treatment of m CRC, given the relevant efficacy in terms of progression-free survival, overall survival, response rate, and quality of life observed in several phase Ⅲ clinical trials among different lines of treatment. However, the anti-EGFR mo Abs were shown only to be effective in a subset of patients. For instance, KRAS and NRAS mutations have been identified as biomarkers of resistance to these drugs, improving the selection of patients who might derive a benefit from these treatments. Nevertheless, several other alterations might affect the response to these drugs, and unfortunately, even the responders eventually become resistant by developing secondary(or acquired) resistance in approximately 13-18 mo. Several studies highlighted that the landscape of responsible alterations of both primary and acquired resistance to anti-EGFR drugs biochemically converge into MEK-ERK and PIK3CA-AKT pathways. In this review, we describe the currently known mechanisms of primary and acquired resistance to anti-EGFR mo Abs together with the various strategies evaluated to prevent, overcame or revert them. | Vincenzo Sforza Erika Martinelli Fortunato Ciardiello Valentina Gambardella Stefania Napolitano Giulia Martini Carminia della Corte Claudia Cardone Marianna L Ferrara Alfonso Reginelli Giuseppina Liguori Giulio Belli Teresa Troiani | 2016 | World Journal of Gastroenterology2016，22，28： | 6 |
| 5 | Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients显示文摘AIM:To investigate the effects of different immunosuppressive regimens and avoidance on fibrosis progression in hepatitis C virus(HCV)liver transplant(LT)recipients.METHODS:We retrospectively compared the liver biopsies of well-matched HCV LT recipients under calcineurin inhibitors(CNI group,n=21)and mycophenolate(MMF group,n=15)monotherapy,with those patients who successfully withdrawn immunosuppression(IS)therapy from at least 3 years(TOL group,n=10).To perform the well-matched analysis,all HCV transplanted patients from December 1993 were screened.Only those HCV patients who reached the following criteria were considered for the analysis:(1)at least3 years of post-operative follow-up;(2)patients with normal liver graft function under low dose CNI monotherapy(CNI group);(3)patients with normal liver graft function under antimetabolite(Micophenolate Mofetil or coated mycophenolate sodium)monotherapy(MMF group);and(4)recipients with normal liver function without any IS.We excluded from the analysis recipients who were IS free or under monotherapy for<36 mo,recipients with cirrhosis or with unstable liver function tests.RESULTS:Thirty six recipients were enrolled in the study.Demographics,clinical data,time after LT and baseline liver biopsies were comparable in the three groups.After six years of follow-up,there was no worsening of hepatic fibrosis in the MMF group(2.5±1.5Ishak Units vs 2.9±1.7 Ishak Units,P=0.5)and TOL group(2.7±10.7 vs 2.5±1.2,P=0.2).In contrast,a significant increase in the fibrosis score was observed in the CNI group(2.2±1.7 vs 3.9±1.6,P=0.008).The yearly fibrosis progression rate was significantly worse in the CNI group(0.32±0.35)vs MMF group(0.03±0.31,P=0.03),and TOL group(-0.02±0.27,P=0.02).No differences have been reported in grading scores for CNI group(2.79±1.9,P=0.7),MMF group(3.2±1.5,P=0.9)and TOL group(3.1±1.4,P=0.2).Twenty four patients were treated with low dose ribavirin(8TOL,7 MMF,9 CNI).The hepatitis C titers were comparable in the three groups.No episodes of rejection have been reported despite differences of liver function test in the three groups during the observational period.CONCLUSION:IS withdrawal and MMF monotherapy is safe and seems to be associated with the slowest fibrosis progression in HCV LT recipients. | Tommaso Maria Manzia Roberta Angelico Paolo Ciano Jon Mugweru Kofi Owusu Daniele Sforza Luca Toti Giuseppe Tisone | 2014 | World Journal of Gastroenterology2014，20，34： | 3 |
| 6 | The occlusal plane in the facial context:inter-operator repeatability of a new three-dimensional method显示文摘The repeatability of a non-invasive digital protocol proposed to evaluate the three-dimensional(3D) position of the occlusal plane in the face is assessed.Dental virtual models and soft tissue facial morphology of 20 adult subjects were digitally integrated using a 3D stereophotogrammetric imaging system.The digital 3D coordinates of facial and dental landmarks were obtained by two different operators.Camper's(facial) and occlusal(dental) planes were individuated,and their 3D relationships were measured.The repeatability of the protocol was investigated and showed no significant differences in repeated digitizations.The angle between occlusal and Camper's planes was smaller than 26 in the frontal and horizontal projections.In the sagittal projection,the angle was observed to be,on average,4.9 6.The determined occlusal plane pitch,roll and yaw values show good agreement with previously published data obtained by different protocols.The current non-invasive method was repeatable,without inter-operator differences and can facilitate assessment of healthy subjects. | Riccardo Rosati Alberto Rossetti Marcio De Menezes Virgilio F Ferrario Chiarella Sforza | 2012 | International Journal of Oral Science2012，4，1： | 2 |
| 7 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells显示文摘 | Erika Martinelli Teresa Troiani Elena D’Aiuto Floriana Morgillo Donata Vitagliano Anna Capasso Sarah Costantino Loreta Pia Ciuffreda Francesco Merolla Loredana Vecchione Veerle Vriendt Sabine Tejpar Anna Nappi Vincenzo Sforza Giulia Martini Liberato Berri | 2013 | Int J Cancer2013，，9： | 2 |
| 8 | A Statistical evaluation of Monson's sphere in healthy permanent dentitions in man显示文摘 | Ferrario VF Sforza C Miani A Jr | 1997 | Arch Oral Biol1997，42，5： | 1 |
| 9 | Three-dimensional facial morphometry of attractive adolescent boys and girls显示文摘 | Sforza C Laino A D'Alessio R | | 0，，02： | 1 |
| 10 | Transversus abdominis plane block anesthesia in abdominoplasties 显示文摘 | Sforza M Andjelkov K Zaccheddu R | 2011 | Plast Reconstr Surg2011，128，2： | 1 |
| 11 | Plant-soil relationships of the invnsive annual grass TaenloJhemm caput-medusae:a reciprocal transplant experiment显示文摘 | Blank R B Rene'Sforza | 2007 | Plant Soil2007，298，12： | 1 |
| 12 | Extraction, Semi- Quantification, and Fast On-line Identification of Oligopeptides in Grana Padano Cheese by HPLC- MS显示文摘 | SFORZA S FERRONI L GALAVERNA G | 2003 | AgricFoodChem2003，51，8： | 1 |
| 13 | Decay estimates for second order evolution equations with memory 显示文摘 | Boussouira F A Cannarsa P Sforza D | 2008 | J Funct Anal2008，254，5： | 1 |
| 14 | Obstructive sleep apnea and the metabolic syndrome in an elderly healthy population: the SYNAPSE cohort显示文摘 | Hourfil-Gabin Assoumou Jean-Michel Gaspoz Emilia Sforza Vincent Pichot Sébastien Celle Delphine Maudoux Michel Kossovsky Florian Chouchou Jean-Claude Barthelemy Frédéric Roche | 2012 | Sleep and Breathing2012，，3： | 1 |
| 15 | A three-dimensional quantita- tive analysis of lips in normal young adults 显示文摘 | Ferrario V F Sforza C Serrao G | 2000 | Cleft Palate Craniofae J2000，37，1： | 1 |
| 16 | Sex differences in obstructive sleep apnoea in an elderly French population显示文摘 | Sforza E Chouchou F Collet P | 2011 | Eur Respir J2011，37，5： | 1 |
| 17 | Automatic Oxford-medilog 9 200 sleep staging scoring:comparison with visual analysis显示文摘 | Vandi S | 1996 | J Clin Neurophysiol1996，13，： | 1 |
| 18 | Effects of pul- monary rehabilitation on exercise capacity in patients with COPD : a number needed to treat study显示文摘 | Riario - Sforza GG Incorvaiu C Patemiti F et 81 | 2009 | International Journal of COPD2009，4，： | 1 |
| 19 | Personality, anxiety and mood traits in patients with sleep-related breath- ing disorders: effect of reduced daytime alertness 显示文摘 | Sforza E de Saint Hilaire Z Pelissolo A | 2002 | Sleep Med2002，3，2： | 1 |
| 20 | Time- dependent variation in cerebral and autonomic activity during periodic leg movements in sleep~ Implications for arousal mechanisms显示文摘 | Sforza E Juony C Ibanez V | 2002 | Clin Neuro- physiol2002，113，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员